A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects

NCT02827513 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult Attention-deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG: CTN SR1
DRUG: CTN XR1
DRUG: CTN XR2
DRUG: CTN XR3

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.